Kwality Pharmaceuticals Ltd.
Snapshot View

211.65 +10.05 ▲5.0%

26 July 2021, 04:00:00 P.M.
Volume: 6,000

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.kwalitypharma.com
Financial Indicators
Market Cap 219.61 Cr.
Earnings per share (EPS) 14.60 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) 14.50 Trailing Twelve Months Ending 2021-03
Industry PE 35.25 Trailing Twelve Months Ending 2021-03
Book Value / Share 43.57 Trailing Twelve Months Ending 2021-03
Price to Book Value 4.86 Calculated using Price: 211.65
Dividend Yield 0.00 Period Ending 2020-03
No. of Shares Subscribed 1.04 Cr. 10,376,198 Shares
FaceValue 10
Company Profile

The company ‘Kwality Pharmaceuticals Limited’ was incorporated on May 04, 1983 vide Certificate of Incorporation issued by the Registrar of Companies, Punjab, H.P. and Chandigarh. It is engaged in the business of manufacturing of broad range of finished pharmaceutical formulations in a dosage form. It carries out its production through state-of-the-art manufacturing units situated at 6th Mile Stone, Village Nag Kalan, Majitha Road, Amritsar - 143006, Punjab, which is also its registered/administrative office and another manufacturing facility situated at 1-A Industrial Area, Raja ka bagh, Jassur, Himachal Pradesh. Both of its manufacturing facilities are well equipped and multiple products are manufactured at these facilities. Since incorporation, the company is ever progressing in Domestic and International market based on its commitment towards high quality and timely supplies. It provides specified and quality products for its customers while maintaining honesty, integrity and loyalty to its employees and customers.

The company has the most modern & sophisticated plant, equipments, technique and manpower. The company is ISO-9001:2000 and ISO 14001:2004 certified, and it is working with new SCHEDULE M and W.H.O. norms and certified with GMP and WHO certificate. The company’s production is based on standards laid down in pharmacopeia and technical reports series (TRS) guidelines of WHO (world health organization). 

Milestones

  • 1983: Incorporation of the company on May 04, 1983.
  • 2007: Received ISO Certification.
  • 2008: Commencement of new manufacturing unit at Jassur in Himachal Pradesh.
  • 2009: Received status of Star Export House Certificate.
  • 2012: Turnover increased by 75%.
  • 2013: Incorporation of Subsidiary Company in Africa.
  • 2014: Received WHO certification.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+4.99%
1 Week
+15.66%
1 Month
+45.66%
3 Month
+210.56%
6 Month
+253.04%
1 Year
+504.71%
2 Year
+370.33%
5 Year
+840.67%
7 years 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03
Return on Equity (%) 5.26 4.43 6.54 14.41 16.51 23.13 20.10
Return on Capital Employed (%) 10.52 9.61 12.45 19.74 19.19 21.91 18.49
Return on Assets (%) 2.66 2.21 2.90 5.37 5.29 7.50 6.90

Balance Sheet View Details

Particulars 7 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds 18 19 21 26 30 37 46
Non Curr. Liab. 2 1 3 4 5 8 20
Curr. Liab. 15 17 27 42 62 61 68
Minority Int. 0 -1 -1 -1 -1
Equity & Liab. 35 37 51 71 96 105 132
Non Curr. Assets 13 13 13 18 21 30 43
Curr. Assets 22 24 38 53 75 75 89
Misc. Exp. not W/O 0 0 0 0
Total Assets 35 37 51 71 96 105 132

Profit Loss View Details

Particulars 7 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 60 52 74 98 137 166 139
Other Income 0 0 0 1 1 1 4
Total Income 60 53 75 100 138 167 143
Total Expenditure -56 -49 -69 -89 -126 -151 -125
PBIDT 4 4 5 10 12 16 18
Interest -1 -1 -1 -2 -2 -2 -3
Depreciation -1 -1 -2 -3 -3 -3 -4
Taxation -1 -1 -1 -2 -3 -3 -3
Exceptional Items
PAT 1 1 1 3 4 8 8

Cash Flow View Details

Particulars 7 years 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. -1 1 -3 4 -1 14 6
Cash Fr. Inv. -3 -1 -2 -7 -6 -12 -18
Cash Fr. Finan. 3 1 6 5 5 -2 12
Net Change -1 1 0 2 -1 0 0
Cash & Cash Eqvt 1 1 1 3 2 1 2

Shareholding Pattern View Details

9 Qtrs 2017-03 (%) 2017-09 (%) 2018-03 (%) 2018-09 (%) 2019-03 (%) 2019-09 (%) 2020-03 (%) 2020-09 (%) 2021-03 (%)
Promoter 50.14 50.14 50.14 50.14 50.14 50.14 51.52 51.52 54.13
Public 49.86 49.86 49.86 49.86 49.86 49.86 48.48 48.48 45.87
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Announcements View Details

Fri, 16 Jul 2021
Statement Of Investor Complaints For The Quarter Ended June 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter
0000
Name of the Signatory :- GURPREET KAUR
Designation :- Company Secretary and Compliance Officer
Fri, 16 Jul 2021
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018
With reference to the captioned subject please find enclosed herewith confirmation certificate issued in accordance with Regulation 74(5) of the SEBI (Depositories and Participants) Regulations 2018 for the Quarter ended June 30 2021 as received from Bigshare Services Private Limited the Registrar and Share Transfer Agent of the Company.
Wed, 30 Jun 2021
Standalone And Consolidated Financial Results For The Half Year & Year Ended 31St March 2021
We wish to inform you that at the Board Meeting held today i.e. on Wednesday June 30 2021 the Board of Directors of the Company have inter alia Considered and approved the Audited Standalone and Consolidated Financial Results for the Half Year & Year Ended 31st March 2021 which are enclosed herewith.

Technical Scans View Details

Mon, 26 Jul 2021
Stock Outperforming Benchmark Index in both 1 Week and 3 Month Stock Outperforming Benchmark Index in both 1 Week and 3 Month
Stock Outperforming Sectoral Index in both 1 Week and 3 Month Stock Outperforming Sectoral Index in both 1 Week and 3 Month
Strongly Outperforming Benchmark Index Strongly Outperforming Benchmark Index
Decreasing Relative Strength - Benchmark index Decreasing Relative Strength - Benchmark index
Strongly Outperforming Sectoral Index Strongly Outperforming Sectoral Index

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 168,769.22 703.40 +1.4%
Divi's Laboratories Ltd. 130,349.05 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. 90,021.63 5,411.25 -0.2%
Cipla Ltd. 76,675.40 950.55 +0.3%
Cadila Healthcare Ltd. 61,992.73 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. 58,965.37 4,100.95 +4.7%
Aurobindo Pharma Ltd. 55,837.02 952.95 -1.1%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 58.12 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2021-03 65.69 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 46.13 5,411.25 -0.2%
Cipla Ltd. Consolidated 2021-03 31.88 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 29.06 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 392.16 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2021-03 10.47 952.95 -1.1%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 3.63 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2021-03 14.02 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 5.14 5,411.25 -0.2%
Cipla Ltd. Consolidated 2021-03 4.18 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 4.77 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.83 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2021-03 2.55 952.95 -1.1%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 0.18 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2020-03 0.33 952.95 -1.1%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 10.09 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.53 952.95 -1.1%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 12.53 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.80 952.95 -1.1%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 17,131.99 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2020-03 23,098.51 952.95 -1.1%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 703.40 +1.4%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,910.15 +1.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 5,411.25 -0.2%
Cipla Ltd. Consolidated 2020-03 1,546.98 950.55 +0.3%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 605.55 -1.6%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,100.95 +4.7%
Aurobindo Pharma Ltd. Consolidated 2020-03 2,844.69 952.95 -1.1%